A non-interventional, prospective cohort study of patients with relapsing Multiple Sclerosis (MS) who had initiated cladribine tablets in routine clinical practice
Latest Information Update: 14 Dec 2024
Price :
$35 *
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms Maven4
- 14 Dec 2024 New trial record
- 20 Sep 2024 Results of subgroup analysis based on previous use of disease-modifying therapies (DMTs) by the patients of relapsing Multiple sclerosis, who had initiated cladribine tablets in real world practice, presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.